197079-39-3

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-oxo-, phenylmethyl ester, (2S)-
• CAS NO: 197079-39-3
• Molecular Formula: C19H29NO4Si
• Molecular Weight: 363.529
• Mol File: 197079-39-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-oxo-, phenylmethyl ester, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-oxo-, phenylmethyl ester, (2S)-(197079-39-3)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-oxo-, phenylmethyl ester, (2S)-(197079-39-3)

Safety Data

• Hazardous Substances Data: 197079-39-3(Hazardous Substances Data)

Usage

Classification

Organic compound
The compound is made up of elements commonly found in living organisms, such as carbon, hydrogen, and oxygen, and is classified as an organic compound.

Structure

Complex
The compound has a complex structure, featuring a pyrrolidine ring, an ester group, and a silicon-containing side chain.

Therapeutic activity

Potential
The compound has potential therapeutic activity, making it a valuable candidate for pharmaceutical and medicinal research.

Applications

Pharmaceutical and medicinal research
Due to its potential therapeutic activity, the compound is commonly used in the field of pharmaceutical and medicinal research for the development of new drugs and treatments.

Specific functions and applications

Context-dependent
The specific functions and applications of the compound may vary depending on the context in which it is used, such as the target disease or condition, and the desired outcome of the research.

Scientific value

Unique structure and composition
The compound's unique structure and composition make it a valuable tool for scientific studies and applications in the field of medicine and drug development.

Upstream product

• 79-37-8 oxalyl dichloride 
• 95687-41-5 (2S,4R)-N1-(benzyloxycarbonyl)-4-hydroxy-2-(hydroxymethyl)-pyrrolidine 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 51-35-4 4R-4-hydroxyproline 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 260417-93-4 benzyl (2S,4R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-hydroxypyrrolidine-1-carboxylate 
• 13504-86-4 (2S,4S)-1-benzyloxycarbonyl-4-hydroxyproline 
• 942308-58-9 (2S,4S)-N-Cbz-4-hydroxyprolinol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1219963-29-7 (S)-benzyl 2-((tert-butyldimethylsilyloxy)methyl)-4-(trifluoromethylsulfonyloxy)-2,5-dihydro-1H-pyrrole-1-carboxylate 
• 197079-40-6 1-benzyloxycarbonyl-2(S)-t-butyldimethylsilyloxymethyl-4-methylenepyrrolidine 

Relevant articles and documents

Practical Gram-Scale Synthesis of Iboxamycin, a Potent Antibiotic Candidate

A gram-scale synthesis of iboxamycin, an antibiotic candidate bearing a fused bicyclic amino acid residue, is presented. A pivotal transformation in the route involves an intramolecular hydrosilylation-oxidation sequence to set the ring-fusion stereocenters of the bicyclic scaffold. Other notable features of the synthesis include a high-yielding, highly diastereoselective alkylation of a pseudoephenamine amide, a convergent sp3-sp2 Negishi coupling, and a one-pot transacetalization-reduction reaction to form the target compound's oxepane ring. Implementation of this synthetic strategy has provided ample quantities of iboxamycin to allow for its in vivo profiling in murine models of infection.

Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1- c ][1,4]benzodiazepine (PBD) antitumor agents

A comprehensive SAR investigation of the C2-position of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) monomer antitumor agents is reported, establishing the molecular requirements for optimal in vitro cytotoxicity and DNA-binding affinity. Both carbocyclic and

Spirocycle integrin inhibitors

This invention relates to novel heterocycles, including (S)-2-phenylsulfonylamino-3-???8-(2-pyridinylaminomethyl)-!-1-oxa-2-azaspiro-?4,5!-dec-2-en-3-yl!carbonylamino! propionic acid, which are useful as antagonists of the αv β3 inte